AAPG News & Events

Ascentage Pharma announced that seventeen clinical updates from its core assets were presented at the 31st Congress of the European Hematology Association, EHA2026. Title: "Efficacy of Olverembatinib in patients with chronic-phase chronic myeloid leukemia." Highlights: This study provided the first evidence that olverembatinib is active in patients with ponatinib- and/or asciminib-resistant CP-CML, including those harboring challenging genotypes such as ASXL1 mutations, highlighting its potential as a treatment option for patients with multi-line TKI-resistant disease. Title: "Updated efficacy and safety of olverembatinib." Highlights: These findings support the potential of olverembatinib to induce durable and deep responses in patients with CP-CML without the T315I mutation whose disease was resistant and/or intolerant to first-line TKI therapy, further supporting its role as a second-line treatment option. Title: "The efficacy and safety of switching to olverembatinib." Highlights: Notably, 78.57% of adverse events related to prior TKI therapy improved after patients switched to olverembatinib. These findings support olverembatinib as a potential standard of care for patients with CML-CP previously treated with at least two TKIs. Title: "Updated results of Polaris-1, a global registrational Phase 3 study." Highlights: These findings suggest that olverembatinib combined with low-intensity chemotherapy may induce rapid, deep, and sustained MRD-negative responses in patients with newly diagnosed Ph+ ALL, while maintaining a favorable safety profile, and provide important evidence supporting its use in the frontline setting. Title: "Safety and preliminary efficacy of olverembatinib." Highlights: These findings support the potential of this chemotherapy-free oral dual-targeted regimen to induce rapid and deep remissions, and may provide a novel treatment option for pediatric patients with R/R Ph+ ALL. Title: "Real-world efficacy and safety of Lisaftoclax."

Ascentage Pharma Group announced results from a Phase Ib study evaluating olverembatinib, the company's core product, in combination with bispecific T-cell engager antibody blinatumomab in patients with lymphoid blast phase chronic myeloid leukemia or Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia were presented in a rapid oral presentation at the 2026 American Society of Clinical Oncology, ASCO, Annual Meeting. Key Highlights: Efficacy Data: A total of 91% of patients achieved complete response or complete response with incomplete hematologic recovery. In addition, 67% of patients achieved BCR::ABL1 negativity by PCR, and 80% achieved minimal residual disease, MRD, negativity by flow cytometry. Conclusion: This study is the first to demonstrate the feasibility of olverembatinib combined with immunotherapy in international patients with CML-LBP and R/R Ph+ BCP-ALL.